Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling results.
Lebedeva A, Timokhin G, Ignatova E, Kavun A, Veselovsky E, Sharova M, Mileyko V, Yakushina V, Kuznetsova O, Stepanova M, Shilo P, Moiseenko F, Volkov N, Plaksa I, Isaev A, Gayryan M, Artemyeva E, Zhabina A, Kramchaninov M, Shamrikova V, Pokataev I, Rumyantsev A, Ledin E, Tryakin A, Fedyanin M, Ivanov M. Lebedeva A, et al. Among authors: rumyantsev a. Clin Exp Med. 2023 Oct;23(6):2663-2674. doi: 10.1007/s10238-023-01011-6. Epub 2023 Feb 8. Clin Exp Med. 2023. PMID: 36752890
Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
Pokataev I, Kudaibergenova A, Artemyeva A, Popova A, Rumyantsev A, Podluzhny D, Kudashkin N, Fedyanin M, Tryakin A, Tjulandin S. Pokataev I, et al. Among authors: rumyantsev a. J Gastrointest Cancer. 2019 Sep;50(3):478-484. doi: 10.1007/s12029-018-0103-6. J Gastrointest Cancer. 2019. PMID: 29675723
Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.
Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S, Tryakin A, Rumyantsev A, Tjulandin S. Pokataev I, et al. Among authors: rumyantsev a. ESMO Open. 2020;5(1):e000578. doi: 10.1136/esmoopen-2019-000578. Epub 2020 Sep 30. ESMO Open. 2020. PMID: 33551067 Free PMC article. Review.
Evidence blocks for effective presentation of genomic findings at molecular tumor boards: Single institution experience.
Lebedeva A, Kuznetsova O, Ivanov M, Kavun A, Veselovsky E, Belova E, Mileyko V, Yakushina V, Shilo P, Tryakin A, Rumyantsev A, Moiseenko F, Fedyanin M, Nosov D. Lebedeva A, et al. Among authors: rumyantsev a. Heliyon. 2024 Apr 26;10(9):e30303. doi: 10.1016/j.heliyon.2024.e30303. eCollection 2024 May 15. Heliyon. 2024. PMID: 38707351 Free PMC article.
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3).
Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL. Tran B, et al. Among authors: rumyantsev a. Cancer Med. 2020 Jan;9(1):116-124. doi: 10.1002/cam4.2674. Epub 2019 Nov 12. Cancer Med. 2020. PMID: 31715650 Free PMC article.
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.
Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. Fankhauser CD, et al. Among authors: rumyantsev a. Eur Urol Focus. 2021 Sep;7(5):1130-1136. doi: 10.1016/j.euf.2020.09.017. Epub 2020 Oct 6. Eur Urol Focus. 2021. PMID: 33032968 Free article.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
114 results